Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Zyprexa
|
| gptkbp:activities |
dopamine receptor antagonist
serotonin receptor antagonist |
| gptkbp:approves |
gptkb:legislation
gptkb:1996 gptkb:United_States |
| gptkbp:brand |
gptkb:Zyprexa_Relprevv
gptkb:Zyprexa_Zydis |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
studies for agitation in dementia
studies for anxiety disorders studies for bipolar disorder studies for depression studies for schizophrenia |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to olanzapine |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
10 mg
5 mg 20 mg |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
orally disintegrating tablet
long-acting injection |
| https://www.w3.org/2000/01/rdf-schema#label |
olanzapine
|
| gptkbp:ingredients |
C17 H20 N4 S
|
| gptkbp:interacts_with |
antidepressants
CNS depressants antihypertensives anticonvulsants |
| gptkbp:is_atype_of |
N05 A H03
|
| gptkbp:is_available_on |
gptkb:tablet
injectable solution |
| gptkbp:is_monitored_by |
gptkb:CBC
gptkb:weight blood pressure lipid profile blood glucose |
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder |
| gptkbp:lifespan |
21 hours
|
| gptkbp:manager |
oral
intramuscular |
| gptkbp:marketed_as |
gptkb:Zyprexa
|
| gptkbp:rounds |
hepatic metabolism
|
| gptkbp:side_effect |
metabolic syndrome
drowsiness constipation dry mouth weight gain increased appetite hyperlipidemia hyperglycemia extrapyramidal symptoms neuroleptic malignant syndrome |
| gptkbp:symptoms |
anxiety
nausea vomiting restlessness insomnia |